 | • レポートコード：MRC2102QY1756 • 出版社/出版日： / 2021年1月 • レポート形態：英文、PDF、148ページ • 納品方法：Eメール（受注後2~3営業日） • 産業分類：医薬品、医療 |
| Single User | ￥600,000 (USD4,000) | ▷ お問い合わせ |
| Multi User | ￥900,000 (USD6,000) | ▷ お問い合わせ |
| Enterprise License | ￥1,200,000 (USD8,000) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYリサーチ社の本調査レポートでは、世界の良性前立腺肥大症（BPH）治療薬市場について種類別（α遮断薬、ホスホジエステラーゼ5型阻害剤、その他）、用途別（病院、ドラッグストア、その他）、地域別（米国、ヨーロッパ、中国、日本、東南アジア、インド）に区分して調査し、纏めました。2015年～2026年までの市場規模予測、主要プレイヤーの競争状況・市場シェア・企業情報、製造コスト分析、販売チャネル・流通業者・顧客情報、市場動向・機会・課題などのマーケットデータが記載されています。市場予測データは新型コロナウイルスの影響を反映させました。 ・良性前立腺肥大症（BPH）治療薬市場の概要 ・世界の主要地域別良性前立腺肥大症（BPH）治療薬市場規模2015-2026 ・主要プレイヤーの競争状況・市場シェア ・世界の良性前立腺肥大症（BPH）治療薬市場規模2015-2026：種類別（α遮断薬、ホスホジエステラーゼ5型阻害剤、その他） ・世界の良性前立腺肥大症（BPH）治療薬市場規模2015-2026：用途別（病院、ドラッグストア、その他） ・良性前立腺肥大症（BPH）治療薬の米国市場規模2015-2020 ・良性前立腺肥大症（BPH）治療薬のヨーロッパ市場規模2015-2020 ・良性前立腺肥大症（BPH）治療薬の中国市場規模2015-2020 ・良性前立腺肥大症（BPH）治療薬の日本市場規模2015-2020 ・良性前立腺肥大症（BPH）治療薬の東南アジア市場規模2015-2020 ・良性前立腺肥大症（BPH）治療薬のインド市場規模2015-2020 ・主要プレイヤーの企業情報：事業概要・売上・企業動向 ・良性前立腺肥大症（BPH）治療薬の製造コスト分析 ・販売チャネル、流通業者、顧客 ・良性前立腺肥大症（BPH）治療薬の市場動向・機会・課題 ・調査の結論 |
BPH is an enlarged prostate. The prostate goes through two main growth cycles during a man’s life. The first occurs early in puberty, when the prostate doubles in size. The second phase of growth starts around age 25 and goes on for most of the rest of a man’s life. BPH most often occurs during this second growth phase.
North America is the largest consumption place, with a consumption market share nearly 38% in 2019. Following North America, Europe is the second largest consumption place with the consumption market share of 27.6%. Market competition is intense. Eli Lilly, GlaxoSmithKline, Astellas Pharma, Sanofi, Pfizer, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers.
Market Analysis and Insights: Global Benign Prostatic Hyperplasia (BPH) Drugs Market
The global Benign Prostatic Hyperplasia (BPH) Drugs market size is projected to reach US$ 3482.1 million by 2026, from US$ 3294 million in 2020, at a CAGR of 0.9% during 2021-2026.
Global Benign Prostatic Hyperplasia (BPH) Drugs Scope and Market Size
The global Benign Prostatic Hyperplasia (BPH) Drugs market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Benign Prostatic Hyperplasia (BPH) Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2015-2026.
Segment by Type, the Benign Prostatic Hyperplasia (BPH) Drugs market is segmented into
Alpha-Blocker
Phosphodiesterase Type-5 Inhibitors
Others
The classification of Benign Prostatic Hyperplasia (BPH) Drugs includes Alpha-Blocker, Phosphodiesterase Type-5 Inhibitors and Others. And the proportion of M Alpha-Blocker in 2019 is about 38%.
Segment by Application, the Benign Prostatic Hyperplasia (BPH) Drugs market is segmented into
Hospitals
Drugstores
Others
Benign Prostatic Hyperplasia (BPH) Drugs is widely used in Hospitals, Drugstores and Others. The most proportion of Benign Prostatic Hyperplasia (BPH) Drugs is used in Hospitals, and the proportion in 2019 is 48.97%.
The Benign Prostatic Hyperplasia (BPH) Drugs market is analysed and market size information is provided by regions (countries). Segment by Application, the Benign Prostatic Hyperplasia (BPH) Drugs market is segmented into United States, Europe, China, Japan, Southeast Asia, India and Rest of World.
The report includes region-wise market size for the period 2015-2026. It also includes market size and forecast by players, by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Benign Prostatic Hyperplasia (BPH) Drugs Market Share Analysis
Benign Prostatic Hyperplasia (BPH) Drugs market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Benign Prostatic Hyperplasia (BPH) Drugs business, the date to enter into the Benign Prostatic Hyperplasia (BPH) Drugs market, Benign Prostatic Hyperplasia (BPH) Drugs product introduction, recent developments, etc.
The major vendors covered:
Eli Lilly
GlaxoSmithKline
Astellas Pharma
Sanofi
Pfizer
Abbott
Allergan
TEVA
Mylan
Novartis
Merck
1 Benign Prostatic Hyperplasia (BPH) Drugs Market Overview
1.1 Benign Prostatic Hyperplasia (BPH) Drugs Product Scope
1.2 Benign Prostatic Hyperplasia (BPH) Drugs Segment by Type
1.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2020-2026)
1.2.2 Alpha-Blocker
1.2.3 Phosphodiesterase Type-5 Inhibitors
1.2.4 Others
1.3 Benign Prostatic Hyperplasia (BPH) Drugs Segment by Application
1.3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Comparison by Application (2020-2026)
1.3.2 Hospitals
1.3.3 Drugstores
1.3.4 Others
1.4 Benign Prostatic Hyperplasia (BPH) Drugs Market Estimates and Forecasts (2015-2026)
1.4.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2015-2026)
1.4.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate (2015-2026)
1.4.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Price Trends (2015-2026)
2 Benign Prostatic Hyperplasia (BPH) Drugs Estimate and Forecast by Region
2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Region: 2015 VS 2020 VS 2026
2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Retrospective Market Scenario by Region (2015-2020)
2.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region (2015-2020)
2.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region (2015-2020)
2.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Estimates and Forecasts by Region (2021-2026)
2.3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Estimates and Forecasts by Region (2021-2026)
2.3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast by Region (2021-2026)
2.4 Geographic Market Analysis: Market Facts & Figures
2.4.1 United States Benign Prostatic Hyperplasia (BPH) Drugs Estimates and Projections (2015-2026)
2.4.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Estimates and Projections (2015-2026)
2.4.3 China Benign Prostatic Hyperplasia (BPH) Drugs Estimates and Projections (2015-2026)
2.4.4 Japan Benign Prostatic Hyperplasia (BPH) Drugs Estimates and Projections (2015-2026)
2.4.5 Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Estimates and Projections (2015-2026)
2.4.6 India Benign Prostatic Hyperplasia (BPH) Drugs Estimates and Projections (2015-2026)
3 Global Benign Prostatic Hyperplasia (BPH) Drugs Competition Landscape by Players
3.1 Global Top Benign Prostatic Hyperplasia (BPH) Drugs Players by Sales (2015-2020)
3.2 Global Top Benign Prostatic Hyperplasia (BPH) Drugs Players by Revenue (2015-2020)
3.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Benign Prostatic Hyperplasia (BPH) Drugs as of 2019)
3.4 Global Benign Prostatic Hyperplasia (BPH) Drugs Average Price by Company (2015-2020)
3.5 Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Sites, Area Served, Product Type
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3.7 Primary Interviews with Key Benign Prostatic Hyperplasia (BPH) Drugs Players (Opinion Leaders)
4 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Type
4.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Historic Market Review by Type (2015-2020)
4.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2015-2020)
4.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Type (2015-2020)
4.1.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Type (2015-2020)
4.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Estimates and Forecasts by Type (2021-2026)
4.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Type (2021-2026)
4.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast by Type (2021-2026)
4.2.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Price Forecast by Type (2021-2026)
5 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Application
5.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Historic Market Review by Application (2015-2020)
5.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2015-2020)
5.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Application (2015-2020)
5.1.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Application (2015-2020)
5.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Estimates and Forecasts by Application (2021-2026)
5.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Application (2021-2026)
5.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast by Application (2021-2026)
5.2.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Price Forecast by Application (2021-2026)
6 United States Benign Prostatic Hyperplasia (BPH) Drugs Market Facts & Figures
6.1 United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Company (2015-2020)
6.2 United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2015-2020)
6.3 United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2015-2020)
7 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Facts & Figures
7.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Company (2015-2020)
7.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2015-2020)
7.3 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2015-2020)
8 China Benign Prostatic Hyperplasia (BPH) Drugs Market Facts & Figures
8.1 China Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Company (2015-2020)
8.2 China Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2015-2020)
8.3 China Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2015-2020)
9 Japan Benign Prostatic Hyperplasia (BPH) Drugs Market Facts & Figures
9.1 Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Company (3015-3030)
9.2 Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2015-2020)
9.3 Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2015-2020)
10 Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Market Facts & Figures
10.1 Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Company (2015-2020)
10.2 Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2015-2020)
10.3 Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2015-2020)
11 India Benign Prostatic Hyperplasia (BPH) Drugs Market Facts & Figures
11.1 India Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Company (2015-2020)
11.2 India Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2015-2020)
11.3 India Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2015-2020)
12 Company Profiles and Key Figures in Benign Prostatic Hyperplasia (BPH) Drugs Business
12.1 Eli Lilly
12.1.1 Eli Lilly Corporation Information
12.1.2 Eli Lilly Business Overview
12.1.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2015-2020)
12.1.4 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
12.1.5 Eli Lilly Recent Development
12.2 GlaxoSmithKline
12.2.1 GlaxoSmithKline Corporation Information
12.2.2 GlaxoSmithKline Business Overview
12.2.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2015-2020)
12.2.4 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
12.2.5 GlaxoSmithKline Recent Development
12.3 Astellas Pharma
12.3.1 Astellas Pharma Corporation Information
12.3.2 Astellas Pharma Business Overview
12.3.3 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2015-2020)
12.3.4 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
12.3.5 Astellas Pharma Recent Development
12.4 Sanofi
12.4.1 Sanofi Corporation Information
12.4.2 Sanofi Business Overview
12.4.3 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2015-2020)
12.4.4 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
12.4.5 Sanofi Recent Development
12.5 Pfizer
12.5.1 Pfizer Corporation Information
12.5.2 Pfizer Business Overview
12.5.3 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2015-2020)
12.5.4 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
12.5.5 Pfizer Recent Development
12.6 Abbott
12.6.1 Abbott Corporation Information
12.6.2 Abbott Business Overview
12.6.3 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2015-2020)
12.6.4 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
12.6.5 Abbott Recent Development
12.7 Allergan
12.7.1 Allergan Corporation Information
12.7.2 Allergan Business Overview
12.7.3 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2015-2020)
12.7.4 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
12.7.5 Allergan Recent Development
12.8 TEVA
12.8.1 TEVA Corporation Information
12.8.2 TEVA Business Overview
12.8.3 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2015-2020)
12.8.4 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
12.8.5 TEVA Recent Development
12.9 Mylan
12.9.1 Mylan Corporation Information
12.9.2 Mylan Business Overview
12.9.3 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2015-2020)
12.9.4 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
12.9.5 Mylan Recent Development
12.10 Novartis
12.10.1 Novartis Corporation Information
12.10.2 Novartis Business Overview
12.10.3 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2015-2020)
12.10.4 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
12.10.5 Novartis Recent Development
12.11 Merck
12.11.1 Merck Corporation Information
12.11.2 Merck Business Overview
12.11.3 Merck Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2015-2020)
12.11.4 Merck Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
12.11.5 Merck Recent Development
13 Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Cost Analysis
13.1 Benign Prostatic Hyperplasia (BPH) Drugs Key Raw Materials Analysis
13.1.1 Key Raw Materials
13.1.2 Key Raw Materials Price Trend
13.1.3 Key Suppliers of Raw Materials
13.2 Proportion of Manufacturing Cost Structure
13.3 Manufacturing Process Analysis of Benign Prostatic Hyperplasia (BPH) Drugs
13.4 Benign Prostatic Hyperplasia (BPH) Drugs Industrial Chain Analysis
14 Marketing Channel, Distributors and Customers
14.1 Marketing Channel
14.2 Benign Prostatic Hyperplasia (BPH) Drugs Distributors List
14.3 Benign Prostatic Hyperplasia (BPH) Drugs Customers
15 Market Dynamics
15.1 Benign Prostatic Hyperplasia (BPH) Drugs Market Trends
15.2 Benign Prostatic Hyperplasia (BPH) Drugs Opportunities and Drivers
15.3 Benign Prostatic Hyperplasia (BPH) Drugs Market Challenges
15.4 Benign Prostatic Hyperplasia (BPH) Drugs Market Restraints
15.5 Porter’s Five Forces Analysis
16 Research Findings and Conclusion
17 Appendix
17.1 Research Methodology
17.1.1 Methodology/Research Approach
17.1.2 Data Source
17.2 Author List
17.3 Disclaimer
Table 1. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) Growth Rate by Type (2020-2026) (US$ Million)
Table 2. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) Comparison by Application (2020-2026) (US$ Million)
Table 3. Global Market Benign Prostatic Hyperplasia (BPH) Drugs Market Size (US$ Million) by Region:2015 VS 2020 &2026
Table 4. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Region (2015-2020)
Table 5. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region (2015-2020)
Table 6. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) Market Share by Region (2015-2020))
Table 7. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Region (2015-2020)
Table 8. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) Forecast by Region (2021-2026)
Table 9. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share Forecast by Region (2021-2026)
Table 10. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) Forecast by Region (2021-2026)
Table 11. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share Forecast by Region (2021-2026)
Table 12. Global Benign Prostatic Hyperplasia (BPH) Drugs (M Units) of Key Companies (2015-2020)
Table 13. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Company (2015-2020)
Table 14. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) by Company (2015-2020)
Table 15. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Company (2015-2020)
Table 16. Global Benign Prostatic Hyperplasia (BPH) Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Benign Prostatic Hyperplasia (BPH) Drugs as of 2019)
Table 17. Global Benign Prostatic Hyperplasia (BPH) Drugs Average Price (US$/Unit) of Key Company (2015-2020)
Table 18. Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Sites and Area Served
Table 19. Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Product Type
Table 20. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 21. Main Points Interviewed from Key Benign Prostatic Hyperplasia (BPH) Drugs Players
Table 22. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Type (2015-2020)
Table 23. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Type (2015-2020)
Table 24. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) Market Share by Type (2015-2020)
Table 25. Global Benign Prostatic Hyperplasia (BPH) Drugs Price (M Units) by Type (2015-2020)
Table 26. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Type (2021-2026)
Table 27. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) Market Share by Type (2021-2026)
Table 28. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Type (2021-2026)
Table 29. Global Benign Prostatic Hyperplasia (BPH) Drugs Price (M Units) by Type (2021-2026)
Table 30. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Application (2015-2020)
Table 31. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Application (2015-2020)
Table 32. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) Market Share by Application (2015-2020)
Table 33. Global Benign Prostatic Hyperplasia (BPH) Drugs Price (M Units) by Application (2015-2020)
Table 34. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Application (2021-2026)
Table 35. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Application (2021-2026)
Table 36. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) Market Share by Application (2021-2026)
Table 37. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Application (2021-2026)
Table 38. Global Benign Prostatic Hyperplasia (BPH) Drugs Price (M Units) by Application (2021-2026)
Table 39. United States Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Company (2015-2020)
Table 40. United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Company (2015-2020)
Table 41. United States Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Type (2015-2020)
Table 42. United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2015-2020)
Table 43. United States Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Application (2015-2020)
Table 44. United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2015-2020)
Table 45. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Company (2015-2020)
Table 46. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Company (2015-2020)
Table 47. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Type (2015-2020)
Table 48. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2015-2020)
Table 49. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Application (2015-2020)
Table 50. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2015-2020)
Table 51. China Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Company (2015-2020)
Table 52. China Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Company (2015-2020)
Table 53. China Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Type (2015-2020)
Table 54. China Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2015-2020)
Table 55. China Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Application (2015-2020)
Table 56. China Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2015-2020)
Table 57. Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Company (2015-2020)
Table 58. Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Company (2015-2020)
Table 59. Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Type (2015-2020)
Table 60. Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2015-2020)
Table 61. Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Application (2015-2020)
Table 62. Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2015-2020)
Table 63. Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Company (2015-2020)
Table 64. Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Company (2015-2020)
Table 65. Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Type (2015-2020)
Table 66. Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2015-2020)
Table 67. Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Type (2015-2020)
Table 68. Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2015-2020)
Table 69. India Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Company (2015-2020)
Table 70. India Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Company (2015-2020)
Table 71. India Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Type (2015-2020)
Table 72. India Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2015-2020)
Table 73. India Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Application (2015-2020)
Table 74. India Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2015-2020)
Table 75. Eli Lilly Corporation Information
Table 76. Eli Lilly Description and Business Overview
Table 77. Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2015-2020)
Table 78. Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 79. Eli Lilly Recent Development
Table 80. GlaxoSmithKline Corporation Information
Table 81. GlaxoSmithKline Description and Business Overview
Table 82. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2015-2020)
Table 83. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 84. GlaxoSmithKline Recent Development
Table 85. Astellas Pharma Corporation Information
Table 86. Astellas Pharma Description and Business Overview
Table 87. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2015-2020)
Table 88. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 89. Astellas Pharma Recent Development
Table 90. Sanofi Corporation Information
Table 91. Sanofi Description and Business Overview
Table 92. Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2015-2020)
Table 93. Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 94. Sanofi Recent Development
Table 95. Pfizer Corporation Information
Table 96. Pfizer Description and Business Overview
Table 97. Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2015-2020)
Table 98. Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 99. Pfizer Recent Development
Table 100. Abbott Corporation Information
Table 101. Abbott Description and Business Overview
Table 102. Abbott Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2015-2020)
Table 103. Abbott Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 104. Abbott Recent Development
Table 105. Allergan Corporation Information
Table 106. Allergan Description and Business Overview
Table 107. Allergan Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2015-2020)
Table 108. Allergan Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 109. Allergan Recent Development
Table 110. TEVA Corporation Information
Table 111. TEVA Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2015-2020)
Table 112. TEVA Description and Business Overview
Table 113. TEVA Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 114. TEVA Recent Development
Table 115. Mylan Corporation Information
Table 116. Mylan Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2015-2020)
Table 117. Mylan Description and Business Overview
Table 118. Mylan Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 119. Mylan Recent Development
Table 120. Novartis Corporation Information
Table 121. Novartis Description and Business Overview
Table 122. Novartis Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2015-2020)
Table 123. Novartis Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 124. Novartis Recent Development
Table 125. Merck Corporation Information
Table 126. Merck Description and Business Overview
Table 127. Merck Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2015-2020)
Table 128. Merck Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 129. Merck Recent Development
Table 130. Production Base and Market Concentration Rate of Raw Material
Table 131. Key Suppliers of Raw Materials
Table 132. Benign Prostatic Hyperplasia (BPH) Drugs Distributors List
Table 133. Benign Prostatic Hyperplasia (BPH) Drugs Customers List
Table 134. Benign Prostatic Hyperplasia (BPH) Drugs Market Key Trends
Table 135. Benign Prostatic Hyperplasia (BPH) Drugs Key Opportunities and Drivers
Table 136. Benign Prostatic Hyperplasia (BPH) Drugs Market Challenges
Table 137. Research Programs/Design for This Report
Table 138. Key Data Information from Secondary Sources
Table 139. Key Data Information from Primary Sources
List of Figures
Figure 1. Benign Prostatic Hyperplasia (BPH) Drugs Product Picture
Figure 2. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type in 2020 & 2026
Figure 3. Type I Product Picture
Figure 4. Type II Product Picture
Figure 5. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Application in 2020 & 2026
Figure 6. Hospitals Examples
Figure 7. Drugstores Examples
Figure 8. Others Examples
Figure 9. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) Growth Rate (2015-2026)
Figure 10. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) Growth Rate (2015-2026)
Figure 11. Global Benign Prostatic Hyperplasia (BPH) Drugs Price Trends Growth Rate (2015-2026) (US$/Unit)
Figure 12. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region: 2015 VS 2020
Figure 13. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region: 2021 VS 2026
Figure 14. United States Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million USD) Growth Rate (2015-2026)
Figure 15. United States Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) Growth Rate (2015-2026)
Figure 16. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million USD) Growth Rate (2015-2026)
Figure 17. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales (Million USD) Growth Rate (2015-2026)
Figure 18. China Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million USD) Growth Rate (2015-2026)
Figure 19. China Benign Prostatic Hyperplasia (BPH) Drugs Sales (Million USD) and Growth Rate (2015-2026)
Figure 20. Japan Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million USD) Growth Rate (2015-2026)
Figure 21. Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales (Million USD) Growth Rate (2015-2026)
Figure 22. Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million USD) Growth Rate (2015-2026)
Figure 23. Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales (Million USD) Growth Rate (2015-2026)
Figure 24. India Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million USD) Growth Rate (2015-2026)
Figure 25. India Benign Prostatic Hyperplasia (BPH) Drugs Sales (Million USD) Growth Rate (2015-2026)
Figure 26. Global 5 Largest Benign Prostatic Hyperplasia (BPH) Drugs Players Market Share by Revenue in Benign Prostatic Hyperplasia (BPH) Drugs 2015 & 2019
Figure 27. Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 28. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Type (2015-2020)
Figure 29. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate by Type in 2015 & 2019
Figure 30. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Application (2015-2020)
Figure 31. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate by Application in 2015 & 2019
Figure 32. United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type in 2019
Figure 33. United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type in 2019
Figure 34. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Company in 2019
Figure 35. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type in 2019
Figure 36. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application in 2019
Figure 37. China Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Company in 2019
Figure 38. China Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type in 2019
Figure 39. China Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application in 2019
Figure 40. Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Company in 2019
Figure 41. Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type in 2019
Figure 42. Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application in 2019
Figure 43. Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Company in 2019
Figure 44. Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type in 2019
Figure 45. Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application in 2019
Figure 46. India Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Company in 2019
Figure 47. India Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type in 2019
Figure 48. India Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application in 2019
Figure 49. Key Raw Materials Price Trend
Figure 50. Manufacturing Cost Structure of Benign Prostatic Hyperplasia (BPH) Drugs
Figure 51. Manufacturing Process Analysis of Benign Prostatic Hyperplasia (BPH) Drugs
Figure 52. Benign Prostatic Hyperplasia (BPH) Drugs Industrial Chain Analysis
Figure 53. Channels of Distribution
Figure 54. Distributors Profiles
Figure 55. Porter's Five Forces Analysis
Figure 56. Bottom-up and Top-down Approaches for This Report
Figure 57. Data Triangulation
Figure 58. Key Executives Interviewed
良性前立腺肥大症用デバイスの世界市場レポート2020 Benign prostatic hyperplasia (BPH) is a urological disorder characterized by non-cancerous proliferation of prostate gland cells. This condition causes the gland to enlarge and, as a result, press against the urethra, constricting urine flow. This disorder is associated with aging, hormone imbalance…- 麻酔薬・鎮痛薬の世界市場レポート2020 Market Analysis and Insights: Global Anaesthetic Drugs and Pain Drugs Market The global Anaesthetic Drugs and Pain Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during 2021-2026. Global Anaesthetic Drugs and Pain Drugs Scope and Market …
- トレプロスチニル薬の世界市場レポート2020 Treprostinil is a vasodilator that is used for the treatment of pulmonary arterial hypertension. North America is the largest consumption place, with a consumption market share nearly 92% in 2018. Following North America, Europe are also very important market with the consumption market share of 6.8…
- アルツハイマー病治療薬の世界市場レポート2020 Market Analysis and Insights: Global Alzheimer's Drugs Market The global Alzheimer's Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during 2021-2026. Global Alzheimer's Drugs Scope and Market Size The global Alzheimer's Drugs market is s…
- 副腎白質ジストロフィー治療薬の世界市場レポート2020 Adrenoleukodystrophy (ALD) is a rare, genetic, X-linked metabolic disorder caused by mutations in the ABCD1 gene that result in a deficiency in a peroxisomal protein called adrenoleukodystrophy protein (ALDP). Adrenoleukodystrophy (ALD) is a disease linked to the X chromosome. It is a result of fatt…